ABSTRACT
Five patients with adverse reactions to peak flow monitoring are presented: 2 patients had herniation of abdominal content, while the others presented with vasovagal syncope, minor depression and neurotic preoccupation with peak flow values, respectively. As a result, 3 of the 5 patients became noncompliant. For nonpsychological somatic adverse reactions, we calculated an incidence of 1.1 cases/1,000 patients started on peak flow monitoring. Adverse reactions with a psychological background may be more frequent. Clinicians should bear in mind that patients noncompliant with peak flow monitoring may have discontinued because of adverse reactions.
Subject(s)
Asthma/physiopathology , Lung Diseases, Obstructive/physiopathology , Respiratory Function Tests/adverse effects , Somatoform Disorders/etiology , Adult , Aged , Aged, 80 and over , Bradycardia/etiology , Female , Hernia, Diaphragmatic/etiology , Humans , Male , Middle Aged , Monitoring, Physiologic/adverse effects , Monitoring, Physiologic/methods , Patient Compliance , Peak Expiratory Flow Rate , Respiratory Function Tests/psychology , Retrospective Studies , Syncope/etiologyABSTRACT
The cephalosporins cefamandole, EMD 29 645, and EMD 29 946 were tested for their nephrotoxicity in female albino Wistar rats (n = 120). The antibiotics were administered i.m. over a course of 5 days; dosage interval 12 h, dosages 1000, 2000, 3000, and 5000 mg/kg per day, respectively. For comparative evaluation of nephrotoxicity, the urinary excretion of tubular cells and enzymes (MDH, GOT, LDH) were taken. Additionally serum urea and urine protein (qualitatively) were determined. Furthermore the kidneys were investigated histologically. These experiments revealed the following tubulotoxic threshold doses: cefamandole: 3000 mg/kg per day, EMD 29 645: 2000 mg/kg per day, and EMD 29 946: 5000 mg/kg per day. EMD 29 645 was also found to be glomerulotoxic at higher doses.
